Program
Day 1 (July 17)
Opening Remarks & Welcome Address
- Toshikazu Ushijima
Session 1: Alterations of Epigenomic Regulators in Cancer
- Bin Tean Teh (National Cancer Centre Singapore)
- Identification of Novel Therapeutic Targets Based on Genomic Information
- Keisuke Kataoka (Keio University)
- Novel Therapeutic Targets in Hematological Malignancies Identified by Genome and Epigenome Analyses
ASPIRE Special Session
- Shinichi Yachida (Osaka University)
- TBA
- Mathieu Lupien (University of Toronto)
- TBA
- Faiyaz Notta (University of Toronto)
- TBA
Luncheon Seminar sponsored by OHARA Pharmaceutical Co., Ltd.
Session 2: Frontiers of Epigenetic Therapy in Solid Tumors
- Hiromu Suzuki (Sapporo Medical University)
- Development and Clinical Application of a DOT1L Inhibitor
- Alfred Cheng (The Chinese University of Hong Kong)
- Clinical Application of Combination Therapy with HDAC Inhibitors and Cancer Immunotherapy
Session 3: Epigenomic Drug Discovery Using Novel Modalities
- Yutaka Kondo (Nagoya University)
- Development and Applications of Novel Nucleic Acid Therapeutics
- Shigehiro Kawashima (The University of Tokyo)
- Chemical Catalyst Manipulating Cancer Epigenome
Sweets Seminar sponsored by KEYENCE CORPORATION
Poster Session
Day 2 (July 18)
Session 4: Epigenetic Therapies Targeting the Tumor Microenvironment
- Kyoko Hida (Hokkaido University)
- Cancer Therapy Targeting Epigenomic Alterations in Vascular Endothelium
- Hyun-Soo Cho (Korea Research Institute of Bioscience and Biotechnology)
- Microbiome-driven epigenetic modulation in cancer: Toward histone methyltransferase-targeted therapeutics
Session 5: Early Cancer Diagnosis Using Epigenomic Alterations
- Young-Joon Kim (Yonsei University)
- Risk Stratification for Hepatocellular Carcinoma Using Liquid Biopsy
- Toshikazu Ushijima (Hoshi University)
- Early Risk Diagnosis Based on Epigenetic Field Defects
Luncheon Seminar sponsored by CyberomiX Co., Ltd.
Session 6: Current Status and Future Perspectives in Hematologic Malignancies
- Makoto Yamagishi (The University of Tokyo)
- Therapeutic Effects and Resistance Mechanisms of EZH1/2 Inhibitors in Hematologic Malignancies
- Shinya Kimura (Saga University)
- Clinical Development of Orally Available Novel DNA Demethylating Agents